Targeting inflammation could help treat drug-resistant bowel cancer
By treating these cells with an inflammation-reducing compound called JQ1, the team was able to overcome the resistance, with the combination of JQ1 and trametinib killing individual cells and halting ...
read more Hemant Kumar Bid
Bid HK, Phelps DA, Xiao L, Guttridge DC, Lin J, London C, Baker LH, Mo X, Houghton PJ. The Bromodomain BET inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma. Mol Cancer Ther.
read more 
Subscribe to RSS Feed